Apremilast 10 mg, 20 mg or 30 mg Glenmark Tablet
PDF Leaflet Revision Date: 14 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of active psoriatic arthritis and moderate to severe chronic plaque psoriasis.
Dosage (summary)
Initial titration from 10 mg to 30 mg twice daily over 5 days; maintenance 30 mg twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Strong CYP3A4 inducers (e.g., rifampicin) reduce efficacy
Contraindications
- Hypersensitivity to apremilast
- Pregnancy
Common side effects
- Diarrhoea
- Nausea
- Vomiting
- Fatigue
- Depression
Counselling Points
- Monitor for mood changes
- Avoid driving until effects are known
- Use contraception in women of childbearing potential
Serious warnings
- Increased risk of depression and suicidal ideation
- Severe gastrointestinal symptoms
Important Disclaimer
The Apremilast 10 mg, 20 mg or 30 mg Glenmark Tablet professional information leaflet below is the property of Glenmark Pharmaceuticals South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
